EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY 4.0

Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma

Benjamin Duy Tran iD, Jing Li, Neang Ly, Raffaella Faggioni, Lorin Roskos

Cancer Chemotherapy and Pharmacology · 2023

DOI: 10.1007/s00280-022-04500-9 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2023. Verfasst von Benjamin Duy Tran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, CA, USA. btran@exelixis.com. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Exelixis, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

In the phase 3 CheckMate 9ER trial, intravenous nivolumab (240 mg every 2 weeks) plus oral cabozantinib (40 mg/day) improved progression-free survival (PFS) versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC). To support cabozantinib dosing with the combination, this exposure–response analysis characterized the relationship of cabozantinib exposure with clinical endpoints.

Methods

Dose modification was allowed with cabozantinib (holds and reductions) to manage adverse events (AEs). The population pharmacokinetics analysis was updated and used to generate individual predicted cabozantinib exposure measures. Kaplan–Meier plots and time-to-event Cox proportional hazard (CPH) exposure–response models characterized the relationship of cabozantinib exposure with PFS, dose modifications, and selected AEs.

Results

Kaplan–Meier plots showed no clear difference in PFS across cabozantinib exposure quartiles. Cabozantinib exposure did not significantly affect the hazard of PFS in the CPH base model nor in the final model. In contrast, baseline albumin and nivolumab clearance had a significant effect on PFS. There was no significant relationship between cabozantinib clearance and risk of dose modification, but a significant relationship was identified between cabozantinib exposure and Grade ≥ 1 palmar-plantar-erythrodysesthesia and Grade ≥ 3 diarrhea in the exposure–response analysis.

Conclusion

To optimize individual cabozantinib exposure, these data support the dose modification strategies in CheckMate 9ER for cabozantinib in patients with advanced RCC when combined with nivolumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Renal CellKidney NeoplasmsHumansAnilidesNivolumabSunitinibPyridines

Stichwörter der Autor:innen

CabozantinibExposure–response analysisNivolumabRenal cell carcinoma

Substanzen

AnilidesAntineoplastic AgentsNivolumabSunitinibcabozantinibPyridines

Autor:innen und Institutionen

  • Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, CA, USA. btran@exelixis.com.
  • Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, CA, USA.

ORCID-Profile: Benjamin Duy Tran

Förderung

  • Exelixis, Inc.

Zitieren

APA

Tran, B. D., Li, J., Ly, N., Faggioni, R., & Roskos, L. (2023). Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-022-04500-9

Vancouver

Tran BD, Li J, Ly N, Faggioni R, Roskos L. Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma. Cancer Chemotherapy and Pharmacology. 2023. doi:10.1007/s00280-022-04500-9

BibTeX
@article{Tran2023,
  author = {Tran, Benjamin Duy and Li, Jing and Ly, Neang and Faggioni, Raffaella and Roskos, Lorin},
  title = {Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2023},
  doi = {10.1007/s00280-022-04500-9}
}
Kostenlos starten →